Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study
Related Experiment Video
Updated: Sep 27, 2026

Dosage-Adjusted Resistance Training in Mice with a Reduced Risk of Muscle Damage
Published on: August 31, 2022
Maggie C Walter1, Peter Reilich, Hanns Lochmüller
1Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Ziemssenstr. 1a, 80336 Munich, Germany. Maggie.Walter@lrz.uni-muenchen.de
Abstract:
We assessed safety and efficacy of creatine monohydrate (Cr) in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to receive Cr and placebo for eight weeks (10.6 g day 1-10, 5.3 g day 11-56) in one of 2 treatment sequences. There was no significant improvement using manual and quantitative muscle strength, daily-life activities, and patients' own global assessment comparing verum with placebo administration. Cr supplementation was well tolerated without clinically relevant side effects, but did not result in significant improvement of muscle strength or daily-life activities.
More Related Videos
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Satellite Stem Cells and Muscular Dystrophy
Alterations in Muscle Tone lll
Alterations in Muscle Tone ll
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

